Neurolixis was recently showcased as the 'Biotech Of The Week" by LaBiotech.eu, the online European biotech networking website. The LaBiotech.eu article drew attention to Neurolixis' CNS drug development programs: NLX-112 for treatment of dyskinesia in Parkinson's disease, a disorder principally found in elderly patients; and NLX-101 for treatment of respiratory dysfunction in Rett syndrome, a rare orphan disorder that manifests itself in young girls.
The Neurolixis drug candidate for treatment of dyskinesia (LID) in Parkinson's disease, NLX-112, was tested in a new study of analgesic activity. It exhibited potent analgesic activity in the mouse formalin test, a model of tonic pain, possibly through activation of spinal cord serotonin 5-HT1A receptors. NLX-112 was also active, albeit less potently, in other pain tests suggesting that it may have beneficial properties on chronic pain symptoms in Parkinson's disease, in addition to its potent anti-dyskinetic activity against L-DOPA-induced dyskinesia (LID), as previously described.
Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain
Sałat K, Kołaczkowski M, Furgała A, Rojek A, Śniecikowska J, Varney MA, Newman-Tancredi A
Neuropharmacology. 2017 Jul 24;125:181-188. doi: 10.1016/j.neuropharm.2017.07.022.